| Phase 1 First-in-human Study of JS014 (NCT05296772) | Anwita Biosciences | 2022-02-28 |
| A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer (NCT04987359) | Pennington Biomedical Research Center | 2021-08-19 |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (NCT04976634) | Merck Sharp & Dohme LLC | 2021-08-18 |
| EMPOWER 3: Improving Palliative Care Health Literacy and Utilization (NCT04733469) | Tulane University | 2021-03-31 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) (NCT04726332) | Exelixis | 2021-02-10 |
| "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. (NCT05818865) | National Cancer Institute, Naples | 2021-01-18 |
| Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance (NCT06332001) | European Institute of Oncology | 2020-12-31 |
| First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL (NCT04401020) | Sanofi | 2020-07-24 |
| AIMS Cancer Outcomes Study (NCT04495790) | Advanced Integrative Medical Science Institute | 2020-05-18 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (NCT03911388) | M.D. Anderson Cancer Center | 2019-09-12 |
| A Study of PSB205 in Subjects With Advanced Solid Tumors (NCT03986606) | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 2019-07-05 |
| A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166) | Exelixis | 2019-03-20 |
| Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients (NCT03873064) | University of Rome Tor Vergata | 2019-01-15 |
| COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (NCT03667716) | Compugen Ltd | 2018-09-06 |
| Shorter Scalp Cooling Time in Paclitaxel (NCT03266185) | Leiden University Medical Center | 2017-12-20 |
| Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors (NCT03324113) | Sanofi | 2017-10-17 |
| Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy (NCT04524728) | Istituti Clinici Scientifici Maugeri SpA | 2016-12-01 |
| A Study of SAR428926 in Patients With Advanced Solid Tumors (NCT02575781) | Sanofi | 2015-10-05 |
| Evaluation of SAR408701 in Patients With Advanced Solid Tumors (NCT02187848) | Sanofi | 2014-07-23 |
| iKnife REIMS Project (NCT04067388) | Imperial College London | 2014-05-01 |
| A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients (NCT01985191) | Sanofi | 2013-11-01 |
| A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma (NCT01943838) | Sanofi | 2013-10-01 |
| A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies (NCT01930552) | Sanofi | 2013-09-01 |
| Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (NCT01836705) | Bristol-Myers Squibb | 2013-05-01 |
| Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients (NCT01657214) | Sanofi | 2012-09-01 |
| A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer (NCT01673737) | Sanofi | 2012-08-01 |
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen (NCT01587040) | Sanofi | 2012-07-20 |
| A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma (NCT01596270) | Sanofi | 2012-06-01 |
| Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment (NCT01527929) | Sanofi | 2012-04-01 |
| A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors (NCT01455532) | Sanofi | 2011-11-01 |
| Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors (NCT01392924) | Sanofi | 2011-08-01 |
| Evaluation of End of Life Quality of Care (NCT03775304) | Assistance Publique - Hôpitaux de Paris | 2011-01-01 |
| First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor (NCT01156870) | Sanofi | 2010-09-08 |
| A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors (NCT01148615) | Sanofi | 2010-07-01 |
| Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment (NCT01140607) | Sanofi | 2010-05-01 |
| A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies (NCT00732992) | Pfizer | 2008-08-01 |